ArticleIDCases2026
Unveiling meropenem-induced thrombocytopenia: Insight from a positive rechallenge case.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meropenem is a broad-spectrum carbapenem antibiotic widely used to treat serious infections.Although generally safe, it can rarely cause drug-induced thrombocytopenia (DITP), a potentially life-threatening condition. We report a case of a 43-year-old male who developed progressive thrombocytopenia after starting meropenem within 3 days, with platelet count recovering upon drug discontinuation. A positive rechallenge with meropenem led to rapid recurrence of thrombocytopenia, giving a probable association. Platelet count improved after permanent cessation of the drug. This case underscores the need for clinicians to be aware of meropenem-induced thrombocytopenia, emphasizing prompt recognition and discontinuation to prevent complications. Regular platelet monitoring during therapy is advised for early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.